UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000011914 |
|---|---|
| Receipt number | R000013914 |
| Scientific Title | A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly HLA-sensitized Transplant Patients. |
| Date of disclosure of the study information | 2013/09/30 |
| Last modified on | 2023/04/08 11:29:32 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2013/09/30 18:10:44 | ||
| 2 | Update | 2018/05/17 20:29:34 | Name of primary person or sponsor Organization |
|
| 3 | Update | 2018/06/12 21:17:24 | UMIN ID1 |
|
| 4 | Update | 2019/02/12 14:53:53 | Public title Public title Acronym Acronym |
|
| 5 | Update | 2019/02/12 14:58:15 | Condition Condition Narrative objectives1 Narrative objectives1 Primary outcomes Primary outcomes |
|
| 6 | Update | 2019/02/12 15:16:21 | Study type Basic design Randomization Blinding Control No. of arms Purpose of intervention Type of intervention Interventions/Control_1 Interventions/Control_1 Key inclusion criteria Key inclusion criteria Key exclusion criteria Key exclusion criteria Target sample size |
|
| 7 | Update | 2019/02/12 15:25:58 | Organization Organization Organization1 Tel1 Email1 |
|
| 8 | Update | 2019/02/12 15:47:46 | Interventions/Control_1 Key inclusion criteria Key inclusion criteria Key exclusion criteria Key exclusion criteria |
|
| 9 | Update | 2020/05/18 18:40:25 | Recruitment status Date of IRB Last follow-up date |
|
| 10 | Update | 2021/10/07 20:00:14 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 11 | Update | 2021/10/11 09:35:53 | Organization1 Tel1 Email1 Organization Organization Tel |
|
| 12 | Update | 2023/04/08 11:29:32 | Recruitment status |
